Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + zoledronic acid
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, and zoledronic acid, a nitrogen-containing bisphosphonate. This combination is used in cancer treatment, particularly for patients with solid tumors and bone metastases. However, clinical studies have shown that this combination may increase the risk, severity, and earlier onset of osteonecrosis of the jaw (ONJ) compared to zoledronic acid alone. The combination appears to enhance anti-angiogenic effects, which may contribute to the increased ONJ risk.
- Other names
- bevacizumab + zoledronateAvastin + zoledronic acidBVZ + ZA
02
Targets
FDPS (Farnesyl pyrophosphate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + zoledronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + zoledronic acid.